Literature DB >> 35089399

Biomedical applications of L-alanine produced by Pediococcus acidilactici BD16 (alaD+).

Anshula Sharma1, Vikrant Mehta2, Suman Rani3, Masafumi Noda4, Masanori Sugiyama4, Harish Chander1,5, Baljinder Kaur6.   

Abstract

L-alanine possesses extensive physiological functionality and tremendous pharmacological significance, therefore could be considered as potential ingredient for food, pharmaceutical, and personal care products. However, therapeutic properties of L-alanine still need to be addressed in detail to further strengthen its utilization as a viable ingredient for developing natural therapeutics with minimum side effects. Thus, the present study was aimed to explore the anticipated therapeutic potential of L-alanine, produced microbially using a lactic acid bacterial strain Pediococcus acidilactici BD16 (alaD+) expressing L-alanine dehydrogenase enzyme. The anticipated therapeutic potential of L-alanine was assessed in terms of anti-proliferative, anti-bacterial, and anti-urolithiatic properties. Anti-bacterial assays revealed that L-alanine successfully inhibited growth and in vitro proliferation of important human pathogens including Enterococcus faecalis, Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus, Streptococcus mutans, and Vibrio cholerae in a concentration-dependent manner. Current investigation has also revealed its significant anti-proliferative potential against human lung adenocarcinoma (A549; IC50 7.32 μM) and mammary gland adenocarcinoma (MCF-7; IC50 8.81 μM) cells. The anti-urolithiatic potential of L-alanine was augmented over three different phases, viz., nucleation inhibition, aggregation inhibition, and oxalate depletion. Further, an in vitro cell culture-based kidney stone dissolution model using HEK293-T cells was also established to further strengthen its anti-urolithiatic potential. This is probably the first in vitro cell culture-based model which experimentally validates the immense therapeutic efficacy of L-alanine in treating urolithiasis disease. KEY POINTS: • Assessment of therapeutic potential of L-alanine produced by LAB. • L-alanine exhibited significant anti-proliferative and anti-bacterial activities. • L-alanine as potential anti-urolithiatic agent.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Anti-bacterial; Anti-proliferative; Anti-urolithiatic; Investigational drug; Kidney stone dissolution; L-alanine; Pediococcus acidilactici BD16; Therapeutics

Mesh:

Substances:

Year:  2022        PMID: 35089399     DOI: 10.1007/s00253-022-11766-9

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  24 in total

Review 1.  Bacteriocins: developing innate immunity for food.

Authors:  Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Nat Rev Microbiol       Date:  2005-10       Impact factor: 60.633

2.  A nuclear magnetic resonance-based demonstration of substantial oxidative L-alanine metabolism and L-alanine-enhanced glucose metabolism in a clonal pancreatic beta-cell line: metabolism of L-alanine is important to the regulation of insulin secretion.

Authors:  Lorraine Brennan; Aine Shine; Chandralal Hewage; J Paul G Malthouse; Kevin M Brindle; Neville McClenaghan; Peter R Flatt; Philip Newsholme
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

3.  Role of Tamm-Horsfall protein and uromodulin in calcium oxalate crystallization.

Authors:  M Carvalho; R A Mulinari; Y Nakagawa
Journal:  Braz J Med Biol Res       Date:  2002-10-13       Impact factor: 2.590

4.  Drying cells for SEM, AFM and TEM by hexamethyldisilazane: a study on hepatic endothelial cells.

Authors:  F Braet; R De Zanger; E Wisse
Journal:  J Microsc       Date:  1997-04       Impact factor: 1.758

5.  Antibacterial activity of copper-amino acid complexes.

Authors:  M S Iqbal; S J Khurshid; M Z Iqbal
Journal:  J Pak Med Assoc       Date:  1990-09       Impact factor: 0.781

6.  Biotransformation of rice bran to ferulic acid by pediococcal isolates.

Authors:  Baljinder Kaur; Debkumar Chakraborty; Gundeep Kaur; Gaganjot Kaur
Journal:  Appl Biochem Biotechnol       Date:  2013-04-25       Impact factor: 2.926

7.  Anticancer activity of small amphipathic β²,²-amino acid derivatives.

Authors:  Terkel Hansen; Dominik Ausbacher; Zack G Zachariassen; Trude Anderssen; Martina Havelkova; Morten B Strøm
Journal:  Eur J Med Chem       Date:  2012-10-05       Impact factor: 6.514

8.  Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted C(α) amino acids.

Authors:  Rickey P Hicks
Journal:  Bioorg Med Chem       Date:  2016-06-25       Impact factor: 3.641

9.  Metabolic engineering of Pediococcus acidilactici BD16 for production of vanillin through ferulic acid catabolic pathway and process optimization using response surface methodology.

Authors:  Baljinder Kaur; Debkumar Chakraborty; Balvir Kumar
Journal:  Appl Microbiol Biotechnol       Date:  2014-07-31       Impact factor: 4.813

10.  Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC1.

Authors:  Nam E Joo; Kathryn Ritchie; Pachiyappan Kamarajan; Di Miao; Yvonne L Kapila
Journal:  Cancer Med       Date:  2012-10-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.